TARS — Tarsus Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $1.20bn
- $1.00bn
- $17.45m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 57 | 25.8 | 17.4 |
Cost of Revenue | |||||
Gross Profit | — | — | 55 | 24.9 | 15.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 4.55 | 27 | 69.2 | 88.5 | 161 |
Operating Profit | -4.55 | -27 | -12.2 | -62.7 | -143 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4.67 | -26.8 | -13.8 | -62.1 | -136 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.67 | -26.8 | -13.8 | -62.1 | -136 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.67 | -26.8 | -13.8 | -62.1 | -136 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.67 | -26.8 | -13.8 | -62.1 | -136 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.24 | -1.31 | -0.673 | -2.52 | -4.62 |
Dividends per Share |